| Targeted therapy strategies against SARS‐CoV‐2 cell entry mechanisms: a systematic review of in vitro and in vivo studies S Seyedpour, B Khodaei, AH Loghman, N Seyedpour, MF Kisomi, ... Journal of cellular physiology 236 (4), 2364-2392, 2021 | 80 | 2021 |
| Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis M Balibegloo, SA Nejadghaderi, M Sadeghalvad, A Soleymanitabar, ... International Immunopharmacology 96, 107796, 2021 | 17 | 2021 |
| The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons SA Nejadghaderi, M Balibegloo, N Rezaei Health Science Reports 7 (6), e2165, 2024 | 13 | 2024 |
| SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury X Yang, HC Chang, Y Tatekoshi, A Mahmoodzadeh, M Balibegloo, ... Elife 12, e85571, 2023 | 11 | 2023 |
| Development and clinical application of bispecific antibody in the treatment of colorectal cancer M Balibegloo, N Rezaei Expert Review of Clinical Immunology 16 (7), 689-709, 2020 | 9 | 2020 |
| Pleural CEA, CA-15–3, CYFRA 21–1, CA-19–9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers FF Khalaf, MA Gharabaghi, M Balibegloo, H Davari, S Afshar, B Jahanbin Int J Biol Markers 38, 81-88, 2023 | 6 | 2023 |
| SIRT2 inhibition protects against cardiac hypertrophy and heart failure X Yang, HC Chang, Y Tatekoshi, M Balibegloo, R Wu, C Chen, T Sato, ... bioRxiv, 2023.01. 25.525524, 2023 | 6 | 2023 |
| Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers F Fazli Khalaf, M Asadi Gharabaghi, M Balibegloo, H Davari, S Afshar, ... The International Journal of Biological Markers 38 (2), 81-88, 2023 | 4 | 2023 |
| Monoclonal antibodies in diabetic retinopathy M Ebrahimi, M Balibegloo, N Rezaei Expert Review of Clinical Immunology 18 (2), 163-178, 2022 | 2 | 2022 |
| Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis SA Nejadghaderi, M Balibegloo, M Noori, F Fayyaz, A Saghazadeh, ... Expert Review of Anticancer Therapy 23 (3), 307-318, 2023 | 1 | 2023 |
| Interdisciplinary approach in gastrointestinal cancers K Danandeh, M Balibegloo, N Rezaei Gastrointestinal Cancers: An Interdisciplinary Approach, 1-16, 2022 | 1 | 2022 |
| Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review SA Nejadghaderi, M Balibegloo, A Saghazadeh, N Rezaei Plos one 17 (7), e0271506, 2022 | 1 | 2022 |
| Introduction on Immune Checkpoints in Cancer M Balibegloo, N Rezaei Handbook of Cancer and Immunology, 1-19, 2023 | | 2023 |
| Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer MT Esfandiyari, M Balibegloo, N Rezaei Lung Cancer Pathophysiology: An Interdisciplinary Approach, 63-89, 2023 | | 2023 |
| Interdisciplinary Approach in Genitourinary Cancers M Shafeghat, M Balibegloo, N Rezaei | | 2022 |
| Tumor Antigen Identification for Cancer Immunotherapy M Balibegloo, M Keshavarz-Fathi, N Rezaei Cancer Immunology: Bench to Bedside Immunotherapy of Cancers, 53-59, 2021 | | 2021 |
Nima RezaeiTehran University of Medical Sciences; Universal Scientific Education and Research Network (USERN)Потвърден имейл адрес: tums.ac.ir
